Form 4: Vera Therapeutics Director Acquires 14,000 Stock Options

Michael Morrissey, a director of Vera Therapeutics, acquired 14,000 stock options on May 14, 2025, exercisable at $21.19.

Summary

• On May 14, 2025, Michael Morrissey, a director of Vera Therapeutics, acquired 14,000 stock options.
• The exercise price of these options is $21.19.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, contingent upon continuous service.
• The options also vest fully upon a change in control, subject to continuous service through that date.
• The expiration date for the options is May 13, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this event alone doesn't strongly indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by a director as a positive sign, aligning the director's interests with the company's success.

Key Dates

Keywords

stock options, director, Vera Therapeutics, beneficial ownership, Form 4, acquisition